ArticlePsychopharmacology2026
Glutamatergic Mechanisms Underlying the Antidepressant-Like Effects of 1-(Phenylselanyl)-2-(p-tolyl)indolizine in Mice.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 1‑(Phenylselanyl)-2‑(ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
rationale1-(Phenylselanyl)-2-(p-tolyl)indolizine (MeSeI) is a selenoindolizine with antidepressant-like properties, modulating monoaminergic system in mice. The mechanisms underlying the antidepressant effects of MeSeI have not been fully elucidated.
objectivesConsidering the important role that the glutamatergic system plays in the pathophysiology of depression, this study aimed to investigate the involvement of N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors signaling in the antidepressant-like effects of MeSeI in forced swimming test (FST) in mice.
methodsFor this purpose, Swiss male mice were pretreated with differents antagonists or agonists; 15-30 min later, MeSeI was administered via the intragastric (i.g.) route. After an additional 30 min, mouse behavior was evaluated using the FST.
resultsThe antidepressant-like effects of MeSeI (50 mg/kg, i.g. route) in the FST were prevented by the pre-treatment with an NMDA receptor agonist (NMDA, 0.1 pmol/site, intracerebroventricular [i.c.v.] route) and a glycine-site NMDA receptor agonist (D-serine, 30 µg/site, i.c.v. route). Co-administration of sub-effective doses of NMDA receptor antagonists (ketamine, 0.01 mg/kg, intraperitoneal [i.p.] route and MK-801, 0.001 mg/kg, i.p. route) with a sub-effective dose of MeSeI (0.5 mg/kg, i.g. route) exerted a synergistic antidepressant-like effect in the FST in mice. However, the results show that the pre-treatment of mice with arcaine (1 mg/kg, i.p. route) or 6,7-dinitroquinoxaline-2,3(1H,4H)-dione (DNQX, 2.5 µg/site, i.c.v. route) was not able to prevent the antidepressant-like effect of MeSeI (50 mg/kg, i.g. route) in the FST.
conclusionsTaken together, our data suggest that NMDA receptor signaling plays a role in the antidepressant-like effects of MeSeI in mice.
Indexed as
Identifiers
40970956What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.